Muntz FH
Researchers are exploring drugs targeting the autophagy pathway to enhance traditional therapies and improve TNBC patient outcomes
Unfortunately, the AGB is far less effective on weight loss as compared to RYGB and VSG (Buchwald et al., 2009), which may be partially due to the fact that AGB does not enhance circulating GLP-1 levels (le Roux et al., 2006)
If you take too much of a GLP-1, you may experience nausea, vomiting, and low blood sugar
Cochrane KM, Elango R, Devlin AM, Mayer C, Hutcheon JA, Karakochuk CD
No other injectable peptide, prescription or research-grade, has produced results at this scale in a controlled human population of comparable size